Coya Therapeutics, Inc. COYA 深 沪
交易中 06-24 11:40:24 美东时间
5.4899
+0.100
+1.85%
华盛通- 最 高5.50
- 今 开5.39
- 成交量 5.75万股
- 最 低 5.335
- 昨 收 5.39
- 总市值 1.29亿
- 52周最高 7.75
- 市盈率 静 --
- 换手率 0.25%
- 52周最低 3.7101
- 委 比 27.71%
- 总股本 2345.72万
- 历史最高 10.6899
- 量 比 0.72
- 振 幅 3.06%
- 历史最低 3.21
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Ciena、Rubrik获多家大行上调目标价；库珀医疗、Guidewire软件、露露乐蒙等遭多家大行下调目标价
今日重点评级关注：瑞银：维持DraftKings"买入"评级，目标价从43美元升至49美元；Needham：维持Planet Labs"买入"评级，目标价从40美元升至53美元
06-08 11:33
Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ:COYA) with a Buy rating and announces Price Target of $12.
06-05 18:29
Coya Therapeutics Q1 EPS $(0.32) Beats $(0.41) Estimate, Sales $251.147K Beat $125.000K Estimate
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.41) by 21.95 percent. This is a 27.27 percent increase over losses of $(0.44) per share from
05-12 19:50
Coya Therapeutics Says FDA Grants Fast Track Designation For COYA 302, Proprietary Investigational Biologic Combination Therapy With Dual Mechanism Of Action, For ALS Treatment
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative
05-12 19:33
Coya Therapeutics Announces Publication Demonstrating That COYA 302 Increased Three Biomarkers In ALS Patients Compared To Controls
The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integrity in 100 randomly selected patients with ALS and included 100 healthy controls to allow for a meaningful comparison.
04-09 20:04
美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
Coya Therapeutics Q4 EPS $(0.34) Misses $(0.28) Estimate, Sales $3.960M Beat $1.928M Estimate
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 21.86 percent. This is a 88.89 percent decrease over losses of $(0.18) per share
03-17 05:56
Coya Therapeutics Files Prospectus To Register Resale Of 2,522,727 Common Shares Issued In Private Placement
Coya Therapeutics, Inc.2,522,727 Shares of Common StockThis prospectus relates to the resale of up to 2,522,727 shares of Coya Therapeutics, Inc. (the "Company," "we," "our," or "us") common stock, par value $0.0001 per
03-16 21:26
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares moved upwards by 70.7% to $0.38 during ...
03-13 05:05
美股大行评级 | 潜在涨幅216.49%！杰富瑞上调BioAge Labs目标价至62美元，评级升至"买入"
今日重点评级关注：杰富瑞：上调BioAge Labs评级至"买入"，目标价从9美元升至62美元；RBC Capital：维持COMPASS Pathways Plc Sponsored ADR"跑赢大市"评级，目标价从21美元升至22美元
02-19 16:21
